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Alexa Clark 
May 11, 2016 
Honors Project Research Summary 
Abstract: 
Ovarian cancer is the most lethal gynecologic malignancy with very ineffective 
efforts at early detection and therapeutic methodologies to reduce mortality. The goal of 
my project is to gain a better understanding of the tumor marker CA-125 in relation to 
ovarian cancer and what steps are being made to better diagnosis early onset ovarian 
cancer. CA-125 marker is not specific or diagnostic for ovarian cancer, but is used for 
therapeutic reasons. This review will summarize current biomarkers and ongoing 
research performed to better diagnose early-onset ovarian cancer. 
Title: 
Is CA-125 the Leading Biomarker in Determining Early-Onset Ovarian Cancer Diagnosis 
in 2016? 
Objectives: 
The goal of this research is to determine why CA-125 is not a useful cancer screening test 
for ovarian cancer and discover other procedures and further research that are being 
performed to better diagnose early-onset ovarian cancer in asymptomatic patients. 
APA Citation Abbreviations:   
Word Abbreviation 
Cancer Antigen  CA 
Human Epididymis Protein HE4 
Parametric Empirical Bayes PEB 
Verses vs. 
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Introduction:  
Epithelian ovarian cancer is composed of different groups of tumors that are 
classified based on their diverse morphology and molecular genetic features: Type II and 
I. Type I is composed of low-grade serous, low-grade endometrioid, clear cell, mucinous, 
and transitional (Brenner) carcinoma. Type II ovarian cancer is highly aggressive, has 
high-grade serous carcinoma, undifferentiated carcinoma and malignant mixed 
mesodermal tumors (carcinosarcoma). Type II describes tumors that arise without 
macroscopic premalignant precursors, making it much harder to diagnose early on. Due 
to the late diagnosis and aggressive progression, Type II is associated with most ovarian 
cancer deaths. 
The most common therapeutic tool used for ovarian cancer is CA-125. CA-125 is 
a high molecular weight trans-membrane glycoprotein that is expressed by coelomic- and 
Mullerian-derived epithelia, including the fallopian tube, endometrium, and endocervix. 
CA-125 is a therapeutic marker that is elevated in the blood of patients with ovarian 
cancer, but it is not diagnostic. This cancer marker is greater in concentration in ovarian 
cancer cells than in other cells, but not specific. The role of CA-125 in the early detection 
of ovarian cancer is extremely controversial and has not been widely accepted for 
screening in women that do not show any symptoms. CA-125 is currently only able to 
detect how the ovarian cancer is responding to treatment and how far along it is.  
Current Diagnosis of Ovarian Cancer: 
Only around 20% of ovarian cancers are found at an early age. If the cancer is 
found early, 94% of patients live longer than five years after diagnosis. Prognosis for 
ovarian cancer is excellent when the detection is at an early stage, but unfortunately this 
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does not happen frequently. This is why the need for an early diagnostic tool is 
significant for ovarian cancer. There are currently two tests that most often used to screen 
for ovarian cancer:  transvaginal ultrasound (TVUS) and CA-125 blood test. [1] Both 
tests are not recommended by major medical or professional organizations for routinely 
screening ovarian cancer due to their inaccuracy. TVUS uses sound waves to look at the 
uterus, fallopian tubes, and ovaries through using an ultrasound wand. It is able to find a 
mass in the ovary, but it cannot determine if a mass is cancer or benign.  
The CA-125 blood test has not been found useful due to other common conditions 
than cancer causing high levels of CA-125. Also, not everyone with ovarian cancer have 
a high CA-125 level. This marker is not only elevated in ovarian cancer, but also elevated 
in benign conditions, such as endometriosis, diseases of the ovary, and menstruation. The 
CA-125 marker can also be elevated in endometrial cancer, fallopian tube cancer, lung 
cancer, breast cancer, and gastrointestinal cancer, proving that it is not specific for just 
ovarian cancer and cannot be solely used as a diagnostic tool without another tumor 
marker. I seek to find out what other tumor markers are substantial in diagnosing early 
onset ovarian cancer regarding the tumor marker CA-125.   
Overview/Methodology:  
In order to enhance the sensitivity for early disease detection there have been 
three notable advances taken. The first approach is obtaining longitudinal measurements 
of CA-125 to calculate the probability of ovarian cancer for a patient using the Bayesian 
algorithm. A longitudinal algorithm involves the change over time in biomarker levels in 
order to individualize screening decision rules. In comparison to a single-threshold (ST) 
rule, smaller deviations from the baseline biomarker levels are made to signal the disease. 
 4 
In this longitudinal algorithm, serial preclinical serum Ca-125 values were measured 
annually in 44 incident ovarian cancer cases that were identified from participants in the 
PLCO (Prostate Lung Colorectal and Ovarian) Cancer Screening Trial. The CA-125 
values were used to determine how frequent the parametric empirical Bayes (PEB) 
longitudinal screening algorithm could identify ovarian cancer earlier than a single-
threshold (ST) rule. [2] 
The second approach uses algorithms to research CA125 and HE4’s significance 
to diagnosing ovarian cancer. Tumor marker human epididymis protein (HE4) was used 
in combination with CA125 to screen asymptomatic women in the general population. 
HE4 is found primarily in the epithelia of normal genital tissues and is made up of a four 
disulfide core and two whey acidic proteins. HE4 is elevated in epithelial cancer, but this 
research determines the specificity and sensitivity in correlation to CA125. HE4 and 
CA125 were analyzed through genomic strategies and the development of algorithms 
Risk of Malignancy Algorithm (ROMA), OVA1, compared to Risk of Malignancy Index 
(RMI). RMI, developed in 1990 by Jacobs et al, is a formula which incorporates a 
woman’s CA125 level, ultrasound score, and menopausal status in order to figure out 
their likelihood of malignancy for the adnexal mass. The recent algorithms developed, 
ROMA and OVA1 are used to evaluate the effectiveness of RMI. ROMA algorithm is 
based on the serum level of HE4 and CA-125 with menopausal status. OVA1 is made up 
of biomarkers through mass spectrometry: β-2 microglobulin, transferrin, transthyretin, 
and apolipoprotein.  
The third approach determined other significant biomarkers that can increase the 
sensitivity and specificity of CA125, in comparison with HE4. This final approach 
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assembles panels of biomarkers to create a “composite marker.” Due to CA125 levels 
occurring in various benign gynecologic conditions, this approach identifies other novel 
biomarkers that can increase the sensitivity and specificity of CA125 through analysis of 
adnexal masses in two hundred and fifty-nine patients.  
Pathogenesis: 
The overall survival of women with ovarian cancer has not changed in over 50 
years because most screening studies have been unsuccessful in providing a survival 
benefit or early diagnostic tool. Currently, most management is directed at cancers that 
are already developed rather than the mechanism of how cancers come about. 
Fortunately, in the last few years there have been significant advances in the field, 
increasing our understanding of ovarian cancer, to improve the outcome [3].  
Ovarian cancer originates from ovarian surface epithelium (mesothelium), which 
invaginates into underlying stroma that results in inclusion cysts. Inclusions cysts 
undergo malignant transformation after they are produced, but this origin and 
pathogenicity is still vastly unclear, which is why diagnosing the disease early on is 
difficult. It is proposed that ovarian cancer develops de novo “nothing will come from 
nothing.” Each year in the United States approximately 21,550 women develop ovarian 
cancer “de novo” and 14,600 women die from ovarian cancer [4]. Although there are 
significant differences between the histologic types of ovarian cancer, the majority of 
ovarian carcinomas are high-grade serious carcinomas. Ovarian cancer can spread from 
the ovary to the abdomen, pelvis, and other distant sites. 
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Relevant Laboratory Data/Discussion:  
At 99% specificity, the PEB algorithm detected ovarian cancer earlier than a ST 
rule in 20% of cases. A CA-125 cutoff of greater than/or equal to 35 U/mL was used. 
Among the 20% of cases, PEB signaled abnormal CA-125 values, at about 10 months 
earlier and at a CA-125 concentration 42% (20U/mL) lower than ST-rule cutoff [2]. Not 
only was this test able to increase the amount of cases diagnosed earlier than normal, it is 
also able to decrease the amount of concentration needed to do so. With use of the PEB 
algorithm, ovarian cancer could potentially be diagnosed 10 months earlier, creating a 
much greater prognosis for the patients.  
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Graph 1: Participant vs. Time to Diagnosis (years) [2]. 
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Graph 1 represents the screening histories for the 44 incident PLCO Cancer 
screening trial ovarian cancer patient cases with two consecutive screens and who’s 
proximate screen falls within the year diagnosed. The numerical values are a 
representation of CA-125 concentrations. The blue concentrations are positive for 
PEB and ST rules at 99% specificity and the black concentrations are negative. The 
red numerical values are PEB positive and ST negative at 99% specificity.  
Through the second approach, HE4 proved to significantly increase the specificity 
with CA-125. Through genomic strategies, HE4 had a similar sensitivity (79%) to CA-
125 but demonstrated a higher specificity (93% vs. 78%) to CA-125 when distinguishing 
between benign diseases from ovarian cancer. HE4 has greater specificity in 
premenopausal age groups than CA-125 because it is not expressed at high levels in the 
setting of benign conditions such as endometriosis.  Still, it is unlikely an individual 
biomarker will reach a specificity of 99.6%, positive predictive value of 10%, and 
sensitivity greater than 75% when screening an asymptomatic general population [5]. 
Progress has been made through developing algorithms to eliminate malignancy with 
using an adnexal mass. Through ROMA and OVA-1, HE4 is also superior to CA-125 
with or without RMI and ROMA indices. HE4 has 98% sensitivity and 100% specificity 
for the detection of ovarian cancer. There is no benefit from combining both markers in 
ROMA and OVA-1[6].  
The third approach demonstrated a potential benefit in combining HE4 and 
CA125 to create a composite marker and quantify risk potential malignancy in the 
evaluation of an adnexal mass through analyzing the levels of different biomarkers in 
their relation to their specificity. The samples analyzed were CA125, SMRP, HE4, 
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CA72-4, activin, inhibin, osteopontin, epidermal growth factor (EGFR), and ERBB2 
(Her2). Out of all the combinations, CA-125 and HE-4 yielded the highest sensitivity at 
76.4% (specificity 95%). Alone, HE4 had the highest sensitivity at 72.9% (specificity 
95%), and no other markers made a substantial significance as a single marker. The best 
marker for Stage 1 disease was HE4, and there was no increase in sensitivity with CA-
125 or any other marker [6].  
Case Conclusion: 
For ovarian cancer screening by using CA125, the PEB longitudinal algorithm 
detected ovarian cancer earlier than an ST rule proving its statistical significance in 
several cases. The PEB longitudinal algorithm identifies ovarian cancer 10 months earlier 
and at lower biomarker concentrations in CA-125 than in ST screening algorithm at the 
same specificity. The longitudinal biomarker assessment through the PEB algorithm 
could potentially be used to screen other solid tumors where biomarkers are available. 
This algorithm shows potential promise for future diagnosis of early-onset ovarian 
cancer. The algorithm is computationally simply, easy to use, and readily adaptable to 
many different biomarkers and screening programs that use early recall [7].  
Through the genomic approaches, HE4 is proved to be a more specific biomarker 
than CA-125 in diagnosing ovarian cancer in patients with pelvic and adnexal masses and 
represents a victory for genomic strategies in the search for effective biomarkers in the 
prediction of malignancy. As a single tumor marker, HE4 had the highest sensitivity for 
detecting stage I disease of ovarian cancer. Although HE4 is more specific than CA-125, 
combined they are more accurate predictors of malignancy than either alone. Still, more 
research needs to be done on increasing the specificity and sensitivity in the 
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asymptomatic population. 
Ca-125 remains a valued tool for monitoring the response to chemotherapy and 
detecting disease relapse after treatment of ovarian cancer. Longer-term studies of CA-
125 are still underway and focusing on identifying the origin of tumor groups will lead to 
more effective screening strategies in asymptomatic populations and improved 
categorization through molecular advances will help to better approximate the time 
course of ovarian cancer. In order to identify early stage disease of ovarian cancer, there 
will need to be a change in the current approaches to include advances made in the 
understanding of tumor heterogeneity in this malignancy. Through the different 
approaches of research, it is clear that the combination of HE4 with CA125 shows 
promise for future diagnoses of early onset ovarian cancer and more research should be 
conducted on the composite marker in order to best diagnose the patient. 
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